Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2014, Vol. 19 ›› Issue (1): 90-95.

Previous Articles     Next Articles

Advance in study on tacrolimus pharmacodynamics

YANG Meng1,2, ZUO Xiao-cong1,2,WANG Jiang-lin1,2,CHEN Qing-Jie1,2   

  1. 1Department of Pharmacy, the Third Xiangya Hospital, Certral South University, Changsha 410013,Hunan,China;
    2School of Pharmaceutical Science, Central South University, Changsha 410013, Hunan,China
  • Received:2013-01-04 Revised:2014-01-09 Online:2014-01-27 Published:2014-02-12

Abstract: Tacrolimus is a kind of calcineurin inhibitor, mainly suppressing the transcription of cytokines IL-2, IL-3, IL-4, IL-5, IFN-γ, TNF-α, GM-CSF and expression of IL-2, IL-17 receptor. In addition, tacrolimus shows remarkable immunosuppressive effects in the prevention and treatment of organ transplant rejection in clinical and animal experiments. Its major adverse reaction includes nephrotoxicity, neurotoxicity, hypertension, posttransplantation diabetes mellitus,gingival hyperplasia, and so on.

Key words: Tacrolimus, Pharmacodynamics, Cytokine, Rejection, Side effect

CLC Number: